

RECEIVED

SEP 18 2000

TECH CENTER 1600/2500

of a composition comprising an agent selected from the group consisting of:

- (a) non-recombinant, NS-specific antiseft activated T-cells;
- (b) a NS-specific antigen or a derivative thereof;
- (c) a peptide derived from a NS-specific antigen or a derivative thereof;
- (d) a nucleotide sequence encoding a NS-specific antigen;
- (e) a nucleotide sequence encoding a peptide derived from a NS-specific antigen; and
- (f) any combination of (a)-(e).

Rewrite claims 3-7 in amended form as follows:

3 (Amended). [The method according to claim 1 or 2 in which said injury comprises] A method in accordance with claim 16, wherein said method is for ameliorating the effects of an injury selected from the group consisting of blunt trauma, penetrating trauma, hemorrhagic stroke, ischemic stroke, [or] and damages caused by surgery.

4 (Amended). [The method of claim 1 or 2 in which said disease is] A method in accordance with claim 16, wherein said method is for ameliorating the effects of a disease selected from the group consisting of Diabetic neuropathy, senile dementia, Alzheimer's disease, Parkinson's Disease,

facial nerve (Bell's) palsy, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, non-arteritic optic neuropathy, [or] and vitamin deficiency.

5 (Amended) [The method of claim 1 or 2 in which said disease] A method in accordance with claim 16, wherein said method is for ameliorating the effects of a disease which is not an autoimmune disease or a neoplasm.

6 (Amended). [The method of claim 1 or 2] A method in accordance with claim 16 in which said peptide derived from a NS-specific antigen is an immunogenic epitope or a cryptic epitope.

7 (Amended). [The method according to claims 1 or 2 in which said] A method in accordance with one of claims 16, 3, 4 or 5, wherein said agent is a NS-specific antigen or a derivative thereof or a peptide derived from a NS-specific antigen or a derivative thereof, and wherein said composition is administered intravenously, intraperitoneally, intramuscularly, subcutaneously, orally, intranasally, vaginally, rectally, intraocularly, intrathecally, intradermally, or buccally.

Delete claim 8 and insert new claim 17 as follows:

*withdrawn*  
17. A method according to claim 16, wherein said agent is an agent of (a), (c), (d) or (e) and further comprising administering to the human in need thereof an

*Bicon* <sup>112nd</sup> effective amount of a composition comprising a NS-specific antigen or a derivative thereof.

Rewrite claims 9 and 10 in amended form as follows:

*introduced*  
~~9~~ (Amended). The method according to claim [8] 17 in which said NS-specific antigen is administered before or after administration of the composition [according to claim 1(a), 1(c), 1(d), 1(e), 2(a), 2(c) or 2(e)] comprising an agent of (a), (c), (d) or (e).

*B3* ~~10~~ (Amended). The method according to claim [8] 17 in which said NS-specific antigen is administered concurrently with administration of the composition [according to claim 1(a), 1(c), 1(d), 1(e), 2(a), 2(c) or 2(e)] comprising an agent of (a), (c), (d) or (e).

Claim ~~11~~, line 1, change "1 or 2" to --16--.

Claim ~~12~~, line 1, change "1 or 2" to --16--.

(13) Claim ~~13~~, line 1, change "1 or 2" to --16--.

Delete claims ~~14~~ and ~~15~~ and substitute therefor new claims 18 and 19 as follows:

*introd*  
~~--18--~~. A method in accordance with claim 16 wherein said agent is a nucleotide sequence of (d) selected from the group consisting of a sequence selected from the group consisting of SEQ ID NOs:1-11. *Wld. NE*